Program
Generic Drug
Also written as “Enter a brief, descriptive name for the intervention. Use a non-proprietary (generic) name, if available. SYS6043” and “Generic 0.5% 5-fluorouracil cream”.
Its studies are mostly in Triple Negative Breast Neoplasms · Keratosis, Actinic, led by 2 companies.
Drug pageGeneric Drug: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CSPC Pharmaceutical Groupits history only | 11 open or running | phase 3since Sep 28, 2026 | Sep 28, 2026 | Nov 30, 2028phase 3 · NCT07879911 |
| Spear Pharmaceuticalsits history only | 10 open or running | phase 3since May 14, 2011 | May 14, 2011 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 14, 2011First study: phase 3 study in Keratosis, ActinicNew to Spear PharmaceuticalsSpear Pharmaceuticals · NCT01354717 · 377 enrolled
- Sep 28, 2026CSPC Pharmaceutical Group’s first study: phase 3 study in Triple Negative Breast NeoplasmsNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT07879911 · 550 planned
Ahead
- Nov 30, 2028Primary completion: phase 3 study in Triple Negative Breast NeoplasmsCSPC Pharmaceutical Group · NCT07879911
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07879911Triple Negative Breast Neoplasms | 3 | Not yet recruiting | CSPC Pharmaceutical Group | Nov 30, 2028 | 550 |
| NCT01354717Keratosis, Actinic | 3 | Completed | Spear Pharmaceuticals | Mar 2011 | 377 |
How it is read
Names in the registry
- “Enter a brief, descriptive name for the intervention. Use a non-proprietary (generic) name, if available. SYS6043”, 1 entry
- “Generic 0.5% 5-fluorouracil cream”, 1 entry
Conditions, from the studies’ own filings
- Triple Negative Breast Neoplasms, 1 study
- Keratosis, Actinic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.